NSCLC
Conditions
Interventions
Experimental group:Iruplinalkib
Sponsors
Second Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Sign informed consent and join the study voluntarily; 2. Pathological diagnosis of ALK positive or ROS1 positive NSCLC; 3. age =18 years old; 4. no targeted therapy contraindications; 5. The investigator judged that Iruak therapy (either monotherapy or combination therapy) was acceptable.
Exclusion criteria
Exclusion criteria: 1.A positive baseline pregnancy test for pregnant, lactating or fertile women; 2.Pulmonary interstitial disease, drug-related pneumonia or other radiation pneumonia that still requires drug intervention; 3.Proven allergy to Iruak and its excipients;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Progression-free survival;Objective Response Rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactSong Xiang
Second Hospital of Shanxi Medical University
Outcome results
None listed